Valneva SE
VALN
View Detailed Chart
8.650USD
-0.190-2.15%
Close 09/05, 16:00（ET）Quotes delayed by 15 min
1.40BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-2.15%
5 Days
-2.26%
1 Month
+9.91%
6 Months
+21.23%
Year to Date
+97.85%
1 Year
+22.28%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-05Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Buy
Current Rating
13.675
Target Price
+54.69%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Fairly Valued
The company’s latest is -18.80, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 665.50K shares, decreasing 31.13% quarter-over-quarter.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 3.26.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Ticker SymbolVALN
CompanyValneva SE
CEOMr. Thomas Lingelbach
Websitehttps://valneva.com/
Related Instruments
+2.33%
-1.08%
+7.24%
+1.96%
+1.80%
+8.66%
+9.16%
+1.92%
+0.96%
-0.84%
+3.93%
+1.08%
+1.34%
+4.67%
+3.17%
+0.39%
+3.38%
+2.82%
0.00%
+1.04%
